©2018 NanoTemper Technologies, Inc. South San Francisco, CA, USA. All Rights Reserved.
data for publishing meaningful results, most researchers only need K
d
to
confirm that two molecules are interacting and whether their affinity is low
or high. For scientists performing either basic research or early-stage drug
development, it is o en important to swi ly measure binding interactions
using very little sample.
Binding kinetics may come into play later, when individual proteins are
investigated further for drug development. In the context of screening
proteins, binding affinity could help identify promising candidates, while
kinetics could provide a deeper analysis of candidates of interest.
Selecting the best approach for measuring ligand-protein
interactions
When deciding what measurements are best for your research, consider
what answer you're looking for and decide if measuring binding affinity is
enough to make the right decision or if you need the depth that binding
kinetics provides.
Also, think about what measurement for screening proteins is most
beneficial in the context of your research. Binding affinity could help
identify promising candidates swi ly using a small amount of sample,
whereas binding kinetics could provide a deeper analysis of candidates
of interest at a later stage of research. While required by the U.S. FDA for
drug approval in certain cases, measuring binding kinetics is not always
necessary for most basic research and early-stage drug development.
Both binding affinity and binding kinetics have their place in researching
protein interactions, but if you consider what data is necessary, you might
find that binding affinity provides enough context. Since obtaining binding
kinetics data can be complex due to the instrumentation and analysis, you
can gain meaningful information from binding affinity measurements and
save your precious sample and time analyzing data.
Reference
1. U.S. Food and Drug
Administration/Center for
Drug Evaluation and Research/
Center for Biologics Evaluation
and Research (2015). Quality
Considerations in Demonstrating
Biosimilarity of a Therapeutic
Protein Product to a Reference
Product Guidance for Industry.
Download the Guide to
Measuring Binding Affinity
nanotempertech.com
